Integra LifeSciences Enters Definitive Agreement To Acquire Acclarent From Ethicon, A Johnson & Johnson MedTech Company, For $275M Cash At Closing And Additional $5M Milestones
Author: Benzinga Newsdesk | December 13, 2023 07:18am
The acquisition will become part of Integra's Codman Specialty Surgical (CSS) division. The ear, nose and throat (ENT) category is a key area of strategic interest and highly complementary to the neurosurgery segment. The transaction is expected to be accretive to Integra's long-range plan.
Integra expects to provide detailed guidance regarding the financial impacts of this transaction upon closing.
Posted In: IART JNJ
